



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	Recombinant human HER3 (human epidermal growth factor receptor 3), encompassing amino acids 20-643 corresponding to the extracellular domain. This construct contains an Fc domain of IgG1 fused to the C-terminus, followed by a C-terminal Avi-Tag™. This protein was affinity purified.
<b>Background:</b>	HER3 (human epidermal growth factor receptor 3, also known as ERBB3) is a transmembrane protein encoded by the ERBB3 gene. HER3 is broadly expressed in human tissues however, increased expression of HER3 has been linked to a variety of solid tumors including ovarian, breast, colon, and gastric cancers and correlates with decreased overall survival in colorectal cancer patients. HER3 has the unique property of being inherently catalytically inactive but still being able to participate in ligand binding, forming heterodimers with nearby receptors of the HER family. The formation of these dimers initiates a cascade of downstream signaling steps critical to cell proliferation. The binding and subsequent phosphorylation of HER3 by HER2 or EGFR (epidermal growth factor receptor) has been found to play a role in tumor growth and drug resistance. Due to its cell surface expression in a variety of cancers and correlation with decreased survival, HER3 is a prospective therapeutic target for antibody-drug conjugate (ADC) development.
<b>Species:</b>	Human
<b>Construct:</b>	HER3 (20-643-Fc(IgG1)-Avi)
<b>Concentration:</b>	1.31 mg/ml
<b>Expression System:</b>	HEK293
<b>Purity:</b>	≥90%
<b>Format:</b>	Aqueous buffer solution.
<b>Formulated In:</b>	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
<b>MW:</b>	98 kDa + glycans
<b>Glycosylation:</b>	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
<b>Genbank Accession:</b>	NM_001982.4
<b>Stability:</b>	At least 6 months at -80°C.
<b>Storage:</b>	-80°C
<b>Instructions for Use:</b>	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
<b>Assay Conditions:</b>	Assay was performed according to NRG1β: HER3 (ERBB3) Chemiluminescent Assay Kit (BPS Bioscience #82548) with various amounts of HER3.
<b>Applications:</b>	Useful for studying the binding of HER3 by ELISA and in cellular assays.

## Quality Control Data

## 4-20% SDS-PAGE Coomassie Staining

Binding of HER3 to NRG1 $\beta$ 